MF
BCRX icon

Magnetar Financial’s BioCryst Pharmaceuticals BCRX Stock Holding History

Magnetar Financial’s Portfolio BCRX Stock Details BCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$162K Buy
+16,172
New +$146K ﹤0.01% 987
2025
Q4 		– Sell
-116,020
Closed -$881K – 945
2025
Q3 		$881K Buy
116,020
+8,058
+7% +$67.1K 0.01% 485
2025
Q2 		$967K Buy
107,962
+82,542
+325% +$769K ﹤0.01% 446
2025
Q1 		$191K Buy
+25,420
New +$205K ﹤0.01% 677
2024
Q4 		– Sell
-17,928
Closed -$136K – 618
2024
Q3 		$136K Buy
+17,928
New +$136K ﹤0.01% 487

Other funds holding BCRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

Magnetar Financial's BCRX Position: Q2 2026 in Review

Magnetar Financial opened a new position in BioCryst Pharmaceuticals (BCRX) in Q2 2026: 16,172 shares worth $162K. The stake represents ﹤0.01% of the portfolio and ranks #987 among its holdings. This is a return to the name: Magnetar Financial previously reported a position in BCRX as recently as Q3 2025.

Magnetar Financial first reported a position in BCRX in Q3 2024 and has held it in 5 quarters since. The position peaked at $967K in Q2 2025. 318 funds tracked by Wall St. Rank hold BCRX as of Q2 2026.

  • Magnetar Financial held 16,172 shares of BioCryst Pharmaceuticals worth $162K as of Q2 2026.
  • BioCryst Pharmaceuticals was a new Magnetar Financial position in Q2 2026.
  • BioCryst Pharmaceuticals made up ﹤0.01% of Magnetar Financial's portfolio in Q2 2026, its #987 holding.
  • Magnetar Financial first reported a position in BioCryst Pharmaceuticals in Q3 2024 and has held it in 5 quarters since.
  • Magnetar Financial's BioCryst Pharmaceuticals position peaked at $967K in Q2 2025.
  • 318 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q2 2026.

Based on Magnetar Financial's 13F filing for Q2 2026, filed 14 Aug 2026.